At TVM Capital Life Science we are creating sustainable value – for patients, the pharmaceutical industry and our investors. Since 1984, TVM Capital Life Science has invested in more than 130 life science companies in Europe, Canada and the United States, currently managing in excess of €900 million from more than 50 investors. With more than two decades of experience in picking promising entrepreneurs, concepts and products for development, and building successful entrepreneurial companies, we are acutely aware of what it takes to build a world class technology, product or company, and astute at supporting management teams to bring companies and projects to value inflection points. https://www.tvm-lifescience.com
Germany is one of the world’s most important providers and exporters of healthcare products and services. The country's innovative medical products set international standards for quality, safety and reliability. German manufacturers and service providers in all health and life sciences segments attract overseas customers and partners and deliver leadership in healthcare innovation. Germany is “the place to be” for innovative solutions and research services in the medical biotechnology field. HEALTH MADE IN GERMANY provides free access to 3.500+ German healthcare companies with its online database. Visit www.health-made-in-germany.com for more information about the German healthcare industry and all our activities.
At Lonza, we provide contract development, clinical and commercial manufacturing services that enable pharma and biotech companies to bring medicines to patients in need. From the building blocks of life to the final drug product, our solutions are created to simplify your outsourcing experience and provide a reliable outcome when you expect it. Our extensive track record includes commercialization of pioneering therapies and manufacturing of a wide variety of biological and chemical drugs. We continuously invest to solve not just the current, but also the future challenges. Together, let’s bring your next medicine to life. https://pharma.lonza.com/
CORAT Therapeutics develops an innovative therapeutic drug composed of a novel fully human neutralizing antibody against COVID-19, which very efficiently neutralizes SARS-CoV-2. Our lead product, COR-101, decreased SARS-CoV-2 load in the lung by more than 99 % in the Hamster COVID-19 model, and induced recovery after 2 days, compared to 7 days untreated. Our overall goal is to realize the vision of an immunotherapeutic remedy for acute COVID-19 cases as fast as possible. In contrast to any vaccine, COR-101 is developed to treat and cure COVID-19 infected patients directly. https://corat-therapeutics.com
Origenis GmbH is a privately held German biopharmaceutical company developing brain- penetrating highly selective small molecule medicines and diagnostics for a variety of neurodegenerative and neuroinflammatory diseases. Origenis leverages its unique capabilities in drug design, compound synthesis, and characterization to engineer a continuous stream of proprietary intellectual property (IP)-protected new chemical entities capable of permeating the blood-brain barrier. Since 2017, Origenis is using a combination of targeted design and phenotypic screening to identify and optimize antiviral small molecules with a novel mode of action. Origenis’ inhibitors show efficacy on multiple strains of DNA and RNA viruses including SARS-CoV-2. https://www.origenis.de/
Richter-Helm BioLogics is a leading and steadily growing, Germany-based cGMP compliant contract manufacturer of biopharmaceuticals specialized in products derived from bacteria and yeasts with a broad technical, developmental and scientific expertise.
Flexibility and highest cGMP standards are our greatest strengths in the development and manufacture of different product classes e.g. rec. proteins, antibodies, pDNA and vaccines. This has been verified by major regulatory bodies including EMA, FDA, ANVISA, PMDA and MFDS as well as by numerous customer audits. Richter-Helm´s two cGMP manufacturing facilities provide a broad range of bioreactor scales with capacities of currently up to 1,500 litres. To support the global pharmaceutical and biotechnological industries Richter-Helm offers highly specialized services with process development and supply of products for clinical trials and commercial material. Especially for pDNA processes a platform production process including a generic and validated QC testing approach is available. https://www.richter-helm.eu
SSS International Clinical Research is a specialist for clinical studies for medicines and medical devices in Europe with almost 28 years of market presence. Until today the CRO (Clinical Research Organization) has operated clinical trials in 22 countries on three continents.
As operations specialist, SSS has developed accSIS, a proprietary Clinical Trial Management Software (CTMS), which enables the company to organize multinational trials with a maximum project oversight and control. Another key success factor is the team of senior specialists with deep insights into clinical operations and a high dedication to the projects of the customers. The results speak for themselves: SSS receives more than 90% of its business from existing customers. In addition, more than 95% of the study sites SSS is working with rate their services as good or very good. www.cro-sss.eu
QIAGEN N.V., a Netherlands-based holding company with operational headquarters in Hilden / Germany, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics and Life Sciences. As of December 31, 2020, QIAGEN employed more than 5,600 people in over 35 locations worldwide. https://www.qiagen.com
YUMAB develops fully human antibodies from target to lead for clients and partners worldwide. Its proprietary antibody platform covers antibody discovery from one of the world’s largest fully human antibody libraries (1011 sequences), to antibody engineering, and lead optimization. The advanced in vitro and on-cell selection technologies pre-design antibody properties, such as interspecies X-reactivity and developability. YUMAB is proud of its high success-rates to all types of antigens, including difficult targets like GPCRs or ion channels. Bioinformatic optimization and in vitro evolution technologies provide a direct path towards optimized lead candidates for all antibody drug formats. https://www.yumab.com/